Lv2
182 积分 2024-04-27 加入
Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201)
7天前
已关闭
The Society of Thoracic Surgeons 2024 Risk Models for Lung Cancer Resection: Continued Refinement and Improved Outcomes
11天前
已关闭
Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?
11天前
已完结
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer
12天前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
13天前
已关闭
Regulation of immune checkpoint molecules in cancer immune evasion and therapy
17天前
已完结
Towards liquid biopsy-based analysis of antitumour immunity
17天前
已完结
Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
17天前
已关闭
Demographic and Clinicopathologic Characteristics of 3723 Patients with Primary Oral Squamous Cell Carcinoma: A Consecutive, Single-Center Study Over 11 Years (2012-2023)
19天前
已完结
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
22天前
已完结
皖公网安备34019202002308
